Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioVex begins dosing in melanoma trial
The melanoma trial is a 50 patient multi-center study. The first dosing took place at the Mary Crowley Medical Research Center, Dallas, Texas. The primary endpoint of the
The melanoma trial is a 50 patient multi-center study. The first dosing took place at the Mary Crowley Medical Research Center, Dallas, Texas. The primary endpoint of the
Orphan drug designation would entitle TolerRx to exclusive marketing rights in the US for seven years should TolerRx be the first company to receive marketing approval for this
The trial will evaluate three escalating dose levels of the vaccine, in approximately 54 healthy adult volunteers and will follow each subject for six months post-vaccination. Avant has
MB07803 is the second of a new class of drugs discovered by Metabasis that regulates glucose production in the liver by inhibiting an enzyme known as fructose 1,6
ITP is a disorder characterized by low platelet counts leaving patients at risk of episodes of spontaneous bruising, mucosal bleeding, and in severe cases intracranial hemorrhage. The multicenter
The primary objectives of the phase I study are to evaluate the safety and dosing of talabostat in combination with chemotherapy in the pediatric population. The decision of
In particular, doxorubicin is widely used in soft-tissue and bone sarcomas, as well as breast, ovarian and endometrial cancers – all potential targets for AP23573 treatment. AP23573 is
The “rolling” submission is an FDA provision, available to drug candidates that have received fast track designation, which allows for completed sections of a biologics license application (BLA)
The deal includes the catalyst manufacturing business and other assets located at the company’s site in Edison, New Jersey. The business had a turnover of almost $60 million
The orphan drug status will become effective if the European Commission approves this recommendation. Amongst other benefits, the designation provides EU market exclusivity for up to ten years